患有扩散性大B细胞淋巴瘤的老年患者在进展后的表现不佳
Hiroyuki Takahashi1, Rika Sakai1, Natsuki Hirose1
1Department of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Journal of clinical and experimental hematopathology : JCEH
|March 30, 2025
概括
患有复发或耐火性扩散性大B细胞淋巴瘤 (DLBCL) 的老年患者的结局不佳. 对于那些在12个月内进展的人来说,生存率明显下降,这凸显了需要更好的初始和救援治疗的需要.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 临床研究 临床研究
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 尽管使用R-CHOP化疗,但复发率很高.
- 老年患者 (>65岁) 患有复发性或耐药性 (R/R) DLBCL,预后尤其具有挑战性.
研究的目的:
- 在日本单中心队列中分析R/R DLBCL老年患者的临床过程和预后.
- 为了确定影响这种患者群体生存的因素.
主要方法:
- 对52名老年患者 (65岁以上) 进行了回顾性调查,这些患者患有R/R DLBCL,接受R-CHOP化疗治疗.
- 评估无进展生存 (PFS),总生存 (OS) 和中枢神经系统 (CNS) 复发的影响.
主要成果:
- 中位数PFS为8.5个月;初始治疗和进展后的中位数OS分别为20.8个月和7.8个月.
- 最初治疗12个月内疾病的进展与明显较差的生存状况有关.
- 中枢神经系统复发并没有显著影响整体存活率.
结论:
- 患有R/R DLBCL的老年患者表现出不良的预后,即使有救援化疗.
- 改进的初始治疗策略对于最大限度地降低进展风险至关重要.
- 迫切需要开发更有效和可行的进展后治疗方法.
相关概念视频
Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...


